Literature DB >> 15550134

Fatal toxic epidermal necrolysis due to lansoprazole.

N R Heaton1, E V J Edmonds, N D Francis, C B Bunker, J C R Bowling, N Morar.   

Abstract

Toxic epidermal necrolysis (TEN) is a serious cutaneous reaction and is most commonly drug induced. It is associated with significant morbidity and mortality. We describe a patient who developed fatal TEN after re-exposure to lansoprazole. Three years previously he presented with erythema multiforme due to the same drug. To our knowledge this is the first published report of TEN occurring with lansoprazole.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550134     DOI: 10.1111/j.1365-2230.2004.01616.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  4 in total

1.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.

Authors:  Noel Frey; Michael Bodmer; Andreas Bircher; Susan S Jick; Christoph R Meier; Julia Spoendlin
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

Review 2.  Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management.

Authors:  Iris M Otani; Aleena Banerji
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

3.  CYP2C19 Gene Profiling as a Tool for Personalized Stress Ulcer Prophylaxis With Proton Pump Inhibitors in Critically Ill Patients - Recommendations Proposal.

Authors:  Petra Bořilová Linhartová; Ondřej Zendulka; Jaroslav Janošek; Natálie Mlčůchová; Michaela Cvanová; Zdeněk Daněk; Radek Kroupa; Ladislava Bartošová; Břetislav Lipový
Journal:  Front Med (Lausanne)       Date:  2022-07-11

4.  Toxic epidermal necrolysis induced by lansoprazole.

Authors:  Tainá Scalfoni Fracaroli; Ludmilla Queirós Miranda; João Luz Sodré; Mário Chaves; Alexandre Gripp
Journal:  An Bras Dermatol       Date:  2013 Jan-Feb       Impact factor: 1.896

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.